Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics narrows Q3 net loss to $8.0 million from $9.4 million

Positive Impact 3 of 5 earnings

AN2 Therapeutics reported third-quarter 2026 results, with net loss narrowing to $8.0 million from $9.4 million a year earlier as research and development and general and administrative expenses declined. The company reported $80.2 million in cash, cash equivalents and investments as of September 30, 2026, and projects that this will fund operations into 2029 under its current plan.

Key points

  • Q3 2026 net loss was $8.0 million ($0.17 per share), versus $9.4 million ($0.31 per share) in Q3 2025.
  • R&D expenses were $5.7 million, down from $7.0 million, and G&A expenses were $2.9 million, down from $3.0 million.
  • Cash, cash equivalents and investments totaled $80.2 million at September 30, 2026, which the company projects will sustain operations into 2029.
  • Global Phase 2 study of oral epetraborole in polycythemia vera is cleared in all planned jurisdictions, with enrollment expected to begin by year-end 2026.

The filing

CompanyAN2 Therapeutics, Inc. (ANTX)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:31 AM ET
Accession number0001193125-26-452660

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:35 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.